Publication Name	World Journal of Gastroenterology
Manuscript ID	9497
Country	United Kingdom

Received	2014-02-14 11:40
Peer-Review Started	2014-02-14 14:14
To Make the First Decision	2014-04-02 19:23
Return for Revision	2014-04-14 08:12
Revised	2014-04-24 00:58
Second Decision	2014-07-25 09:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-07-25 09:49
Articles in Press	2014-07-25 09:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-30 16:46
Publish the Manuscript Online	2014-12-18 17:08

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management
Manuscript Source	Unsolicited Manuscript
All Author List	Roberta Elisa Rossi, Ioanna Parisi, Edward John Despott, Andrew Kenneth Burroughs, James O'Beirne, Dario Conte, Mark Ian Hamilton and Charles Daniel Murray
Funding Agency and Grant Number
Corresponding Author	Roberta Elisa Rossi, MD, Centre for Gastroenterology, Royal Free Hospital, Pond Street, London NW3 2QG, United Kingdom. robertaelisa.rossi@gmail.com
Key Words	Inflammatory bowel disease; Tumour necrosis factor inhibitors; Hypertransaminasemia; Drug-related liver injury; Infliximab
Core Tip	Anti-tumour-necrosis-factor (TNF) agents appear to be safe with a low risk of causing severe liver injury. Standard guidelines for the management of anti-TNF-related liver injury are lacking. Our approach, based on evidence from literature and our centre experience, highlights the need of a multidisciplinary approach and suggests liver biopsy as a key-point in the management decision. We particularly highlight that continuation of the anti-TNF treatment is usually possible, in view of the rarity of severe liver injury and the lack of alternative medical options in case of severe active inflammatory bowel disease.
Publish Date	2014-12-18 17:08
Citation	Rossi RE, Parisi I, Despott EJ, Burroughs AK, O'Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20(46): 17352-17359
URL	http://www.wjgnet.com/1007-9327/full/v20/i46/17352.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i46.17352

Full Article (PDF)	WJG-20-17352.pdf
Full Article (Word)	WJG-20-17352.doc
Manuscript File	9497-Review.doc
Answering Reviewers	9497-Answering reviewers.pdf
Copyright License Agreement	9497-Copyright assignment.pdf
Peer-review Report	9497-Peer review(s).pdf
Scientific Misconduct Check	9497-CrossCheck.jpg
Scientific Editor Work List	9497-Scientific editor work list.pdf